Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Levemir Innolet

Active Ingredient:
insulin detemir
Company:  
Novo Nordisk Limited See contact details
ATC code: 
A10AE05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

DHPC Letter-Levemir® InnoLet® 100 units/ml solution for injection in pre-filled pen & Insulatard® InnoLet® 100 international units/ml suspension for injection in pre-filled pen -UK Discontinuation

{healthcare_pro_orange} For Healthcare Professionals
Novo Nordisk UK in agreement with the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Department of Health and Social Care (DHSC) would like to inform you of the following:Novo Nordisk has decided to discontinue InnoLet (an injectable device for insulin delivery).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Novo Nordisk Limited
Company image
Address
3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA
Telephone
+44 (0)1293 613555
Fax
+44 (0)1293 613535
Customer Care direct line
+44 (0)800 023 2573
Medical Information Direct Line
+44 (0)800 023 2573
Medical Information e-mail
[email protected]
WWW
http://www.novonordisk.co.uk